Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC).

9082Background: Bevacizumab (Bev) combined with chemotherapy improves survival in selected patients (pts) with advanced, nonsquamous NSCLC. However, the benefit of Bev has been questioned in certain populations and optimal selection criteria are debated. Methods: SWOG S0819 randomly assigned 1,313 eligible pts with advanced NSCLC to chemotherapy (+/- Bev) with or without cetuximab. Protocol defined criteria for Bev Exclusion (BE) were > 50% squamous cell (SCCA), cavitary lung lesion, hemoptysis ( > 1/2 tsp), coagulopathy, CNS metastasis (until 6/2013), non-healing wound or fistula, anticoagulation, platelet inhibitor, or INR > 1.5. Investigators or pts could also choose BE assignment. We conducted subset analyses to compare the baseline characteristics and treatment outcomes for Bev-included (BI) versus BE pts, as well as BE subsets defined by the protocol (BE-Inappropriate) or patient/investigator choice (BE-Choice). Results: BI pts (42.2%) had superior outcomes to BE pts (Table). The reason for BE was a...